Tesamorelin

Key Statistics

Statistic	Value	Detail
Visceral Fat Reduction	18.2%	Abdominal fat loss at 26 weeks
IGF-1 Increase	117%	Growth factor elevation
Liver Fat Reduction	37%	NAFLD improvement at 12 months
NAFLD Resolution	35%	Complete fatty liver reversal
Executive Function	P=0.005	Significant cognitive improvement

Mechanism of Action

GHRH Receptor-Mediated GH Release

Tesamorelin binds to GHRH receptors on pituitary somatotrophs, stimulating pulsatile GH release that maintains physiological feedback mechanisms and circadian rhythms. It promotes selective lipolysis in visceral adipose tissue while preserving subcutaneous fat and muscle mass.

Biological Pathways

GHRH Receptor Activation (Primary)

Growth Hormone Releasing Hormone

• Binds pituitary somatotrophs
• Stimulates pulsatile GH release
• Maintains physiological feedback

IGF-1 Mediated Lipolysis (Mediator)

Insulin-like Growth Factor 1

• Stimulates hepatic IGF-1 production
• Promotes selective visceral lipolysis
• Preserves muscle mass

Metabolic Modulation (Supportive)

Metabolic Flexibility Enhancement

• Reduces ectopic fat deposition
• Improves insulin sensitivity
• Enhances metabolic flexibility

Key Mechanism

Pulsatile GH Stimulation

Tesamorelin preserves natural GH pulsatility unlike exogenous growth hormone. It stimulates the body’s own GH production, maintaining circadian rhythms and feedback mechanisms for a physiologically superior approach.

Source: JCEM (2010)

Metric	Value
VAT Reduction (26wk)	15.4%
VAT Reduction (52wk)	17.5%
Placebo Change	-5%
Participants Achieving >8% VAT Reduction	73%

Clinical Findings

Metric	Value	Context
Visceral Fat Reduction	18.2%	Phase 3, 816 patients, 26 weeks
IGF-1 Increase	117%	Mean elevation from baseline
Liver Fat Reduction	37%	MRI-PDFF measurement

FDA-approved for HIV-associated lipodystrophy. Results from two Phase 3 trials (LIPO-010 & CTR-1011) with 816 HIV-infected patients.

Preclinical Effects

Effect	Model	Value
Treatment Well Tolerated	Phase 3 trials	91.2%
Effects Maintained	Continued use	52 weeks
Triglyceride Reduction	VAT responders	20-50 mg/dL
Trunk Muscle Density	Body composition	+4.86 HU

Research Areas

Visceral Fat Reduction — Primary FDA-approved indication

18.2% average VAT reduction at 26 weeks in HIV lipodystrophy patients

Source: JCEM (2010)

Liver Health — NAFLD/NASH treatment potential

37% hepatic fat reduction, 35% NAFLD resolution. Only FDA-approved agent for HIV-associated NAFLD

Source: Lancet HIV (2019)

Cognitive Function — Executive function improvement

Significant improvements in executive function (P=0.005) and response inhibition in older adults

Source: Archives of Neurology (2012)

Body Composition — Muscle quality enhancement

Improvements in muscle density and lean mass area without loss of lean tissue

Source: JCEM (2019)

Dosing Protocols

Standard FDA Protocol

Dose: 2mg daily subcutaneous | Frequency: Once daily | Duration: Continuous (effects reverse on discontinuation)

• Inject in abdomen, rotate sites
• Same time each day recommended
• Effects reverse if discontinued

Cognitive Support Protocol

Dose: 1mg daily | Frequency: 30 min before bedtime | Duration: 20+ weeks, then assess response

• Lower dose than standard lipodystrophy protocol
• Bedtime administration studied
• Based on MCI/aging study

Pharmacokinetics

Parameter	Value
Half-Life	26-38 minutes
Peak Concentration	0.15 hours (9 minutes)
Bioavailability	<4% (typical for peptides)
Stability	Requires reconstitution
Excretion	Renal (peptide fragments)
Metabolism	Peptide hydrolysis

Safety Profile

Issue	Incidence	Severity
Injection site reactions	13.3%	mild
Arthralgia	7.5%	mild
Peripheral edema	5.7%	mild

• Generally well-tolerated with predictable GH-related side effects
• Anti-tesamorlin antibodies detected but no impact on efficacy
• Well-tolerated long-term (52+ weeks)

Compound Information

Property	Value
Type	Synthetic GHRH analog
CAS Number	218949-48-5
Molecular Weight	5,135.9 g/mol
Amino Acids	44
Sequence	Modified GHRH(1-44)
Formula	C221H366N72O67S1

Frequently Asked Questions

References